HC Wainwright Expects Reduced Earnings for PDS Biotechnology

PDS Biotechnology Corporation (NASDAQ:PDSB) – Equities researchers at HC Wainwright reduced their FY2026 earnings per share estimates for PDS Biotechnology in a note issued to investors on Tuesday, September 8th. HC Wainwright analyst J. Pantginis now expects that the company will earn ($0.49) per share for the year, down from their previous forecast of ($0.46). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for PDS Biotechnology’s current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for PDS Biotechnology’s Q4 2026 earnings at ($0.09) EPS, FY2027 earnings at ($0.30) EPS and FY2028 earnings at ($0.23) EPS.

PDS Biotechnology (NASDAQ:PDSB) last issued its earnings results on Thursday, August 13th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.05).

Several other research firms also recently commented on PDSB. Wall Street Zen upgraded shares of PDS Biotechnology from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings raised shares of PDS Biotechnology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $9.00.

PDS Biotechnology Stock Up 7.6%

PDSB opened at $0.32 on Friday. The stock’s fifty day simple moving average is $0.51 and its 200 day simple moving average is $0.78. PDS Biotechnology has a 1-year low of $0.20 and a 1-year high of $1.55. The stock has a market cap of $17.65 million, a PE ratio of -0.49 and a beta of 1.46. The company has a current ratio of 0.57, a quick ratio of 0.57 and a debt-to-equity ratio of 2.73.

Institutional Investors Weigh In On PDS Biotechnology

Institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new stake in PDS Biotechnology during the fourth quarter worth approximately $25,000. Bank of New York Mellon Corp bought a new stake in shares of PDS Biotechnology during the 2nd quarter valued at $60,000. Marshall Wace LLP acquired a new stake in shares of PDS Biotechnology during the 2nd quarter worth $91,000. Jane Street Group LLC acquired a new stake in shares of PDS Biotechnology during the 2nd quarter worth $92,000. Finally, Susquehanna International Group LLP increased its position in shares of PDS Biotechnology by 603.7% in the third quarter. Susquehanna International Group LLP now owns 94,344 shares of the company’s stock worth $95,000 after purchasing an additional 80,937 shares during the period. 26.84% of the stock is currently owned by institutional investors.

About PDS Biotechnology

PDS Biotechnology Group, Inc is a clinical‐stage immunotherapy company focused on the development of targeted treatments for oncology and infectious diseases. The company’s proprietary Amplivant™ adjuvant platform leverages Toll-like receptor 3 activation to prime antigen‐presenting cells, directing robust immune responses against defined tumor and viral antigens. Its lead therapeutic vaccine candidate, PDS‐0101, is designed to treat HPV16‐positive cancers and is being evaluated both as a monotherapy and in combination with checkpoint inhibitors in ongoing Phase 1/2 clinical trials.

Beyond its HPV‐focused program, PDS Biotechnology is advancing a diversified pipeline of immunotherapies incorporating its Amplivant platform.